AzTrials
AzTrials

Attention Deficit Hyperactivity Disorder (ADHD)NCT07037030

Mindfulness ADHD Intervention

A study testing Guided deep breathing in people with Attention Deficit Hyperactivity Disorder (ADHD), run by Boston Children's Hospital at 1 site in United States.

Enrolling by invitation

Enrolling by invitation. The study team selects and invites participants, usually from an existing group of patients.

Sites and contacts
Official record
Search all trials

Trial summary

Attention-deficit/hyperactivity disorder (ADHD) affects approximately 11% of children and adolescents in the United States. Individuals with ADHD experience substantial impairments and burdens across multiple areas of daily living, including peer difficulties, academic difficulties, poor job outcomes, high rates of… Read more about this study

Who is it for?
Ages 7 to 11 years
What is being tested?
Guided deep breathing
Could I receive a placebo?
No, everyone receives an active treatment
How many people
10 participants
Where
1 siteUnited States
Study dates
26 Feb 2026to Jul 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 7 to 11 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Participant age 7 years, 0 months - 11 years, 11 months
  • Parent-reported ADHD diagnosis for the participant

Who cannot join

  • Previous confirmed or suspected diagnosis of intellectual disability
  • Previous confirmed or suspected diagnosis of autism spectrum disorder
  • Currently prescribed non-stimulant medication for the purpose of managing ADHD symptoms
  • Hearing impairments
  • Primary language other than English
  • Known seizure disorder

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

United States1 site
  • Boston Children's Hospital Laboratories of Cognitive Neuroscience

    Brookline, Massachusetts, 02445

Other trials in United States

About this study

Official title: The Investigation of a Mindfulness-Based Intervention for ADHD

Attention-deficit/hyperactivity disorder (ADHD) affects approximately 11% of children and adolescents in the United States. Individuals with ADHD experience substantial impairments and burdens across multiple areas of daily living, including peer difficulties, academic difficulties, poor job outcomes, high rates of co-occurring disorders, and large financial costs. Although there are many well-established, evidence-based treatments for ADHD, many children continue to experience significant impairment and elevated ADHD symptoms even with prolonged treatment. Further, there are several limitations to existing treatment approaches, including medication side effects, difficulty accessing behavioral treatments, and high out-of-pocket costs for behavioral treatments. Thus, there is a crucial need to identify low cost, low burden, alternative or additive intervention approaches for pediatric ADHD.

In the current pilot study, the investigators aim to evaluate responses in behavioral markers of attention to a mindfulness-based intervention. Mindfulness-based interventions (MBIs), including deep breathing, have received considerable research attention regarding their benefits for ADHD symptoms. Deep breathing is a strong candidate as a supplementary MBI intervention for children with ADHD due to its simplistic and easy-to-implement nature. Studies examining the effects of deep breathing on physiological arousal and ADHD symptoms in children have yielded promising results. Children will be led through a brief deep breathing intervention using a novel tool designed to optimize child engagement in deep breathing. This tool is designed to be held in the child's hands and uses a series of haptic vibrations to provide real-time deep breathing pacing guidance. The investigators predict that following a brief deep breathing practice, children with ADHD will demonstrate improved sustained attention, reaction time consistency, and inhibitory control. These areas of attention and behavioral functioning will be assessed using computer tasks.

The investigators plan to use the results of this study to strengthen a future application for grant funding to run a similar trial with many more children. The investigators believe that the results of this and future studies will improve the lives of children with ADHD and their families.

Being tested
Guided deep breathing
Medical subject headings
Attention Deficit Disorder with Hyperactivity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Guided deep breathingBehavioural

    Children will complete a brief, 5-minute, deep breathing intervention using the Domi tool to help maintain a 5-second breath pace

Study groups in NCT07037030
Study groupRoleWhat they receive
Deep Breathing InterventionExperimentalChildren will complete a brief deep breathing intervention
Receives: Behavioral: Guided deep breathing

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Behavioral Performance Metrics

    Behavioral markers of sustained attention and inhibitory control will be assessed using a Go/NoGo task. Omission errors (failing to respond to a Go trial) and reaction time variability (standard deviation of reaction time across all trials) will serve as markers of sustained attention. Commission errors (responding to a NoGo trial) will serve as a marker of inhibitory control.

    Measured: During the single in-person research visit

  2. Neurophysiological Markers

    Electroencephalography (EEG) methods will be used to measure P300 event-related potentials (ERP), a positive inflection occurring around 300ms after a response to task-relevant and irrelevant stimuli that reflects attention orienting, stimulus evaluation, and inhibitory control. Stimulus-locked P300 amplitude in response to correct Go-trials will be a marker of cortical attention processes, while stimulus-locked P300 amplitude in response to NoGo trials will be a marker of cortical inhibitory control processes.

    Measured: During the single in-person research visit

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Jun 2025
  2. Study start26 Feb 2026
  3. Primary completionJul 2026 (estimated)
  4. Study completionJul 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
10 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07037030
Sponsor's protocol ID
IRB-P00051676
Status last verified
Jun 2025
First submitted
17 Jun 2025
Last updated
31 Mar 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Guided deep breathing in people with Attention Deficit Hyperactivity Disorder (ADHD), run by Boston Children's Hospital at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: enrolling by invitation, as of the sponsor's last update on 31 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Behavioral Performance Metrics (time frame: During the single in-person research visit). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Mar 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in